Nutra Pharma (NPHC) Stock Analysis & Winston Score

Nutra Pharma Corp. is a small healthcare company that develops and sells products made from cobra venom. Its main product is Cobroxin, a pain relief product, and it also makes Nyloxin, aimed at treating more severe pain. The company targets everyday consumers dealing with chronic pain and sells through retail and online channels. Nutra Pharma earns money by selling these venom-based products directly to consumers and through distributors. It is a very small U.S.-based company, and its market cap is essentially zero, which signals it operates at a micro-cap or nano-cap level. The operating margin of roughly negative 580% shows the company spends far more than it earns, meaning it is not yet profitable. The biggest risk the company faces is simply surviving — it needs to grow sales significantly and cut losses before it runs out of resources to keep operating.